Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 73.31M | P/E | - | EPS this Y | 68.20% | Ern Qtrly Grth | - |
| Income | -22.37M | Forward P/E | -0.16 | EPS next Y | -26.20% | 50D Avg Chg | -32.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -29.00% |
| Dividend | N/A | Price/Book | 0.92 | EPS next 5Y | - | 52W High Chg | -85.00% |
| Recommedations | 1.50 | Quick Ratio | 10.38 | Shares Outstanding | 10.56M | 52W Low Chg | 18.00% |
| Insider Own | 8.24% | ROA | -49.60% | Shares Float | 5.49M | Beta | 0.90 |
| Inst Own | 69.07% | ROE | -91.68% | Shares Shorted/Prior | 59.08K/66.45K | Price | 2.62 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 313,865 | Target Price | 19.00 |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 65,333 | Change | -9.97% |
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biopharma Inc. News